ATE439378T1 - Verfahren zur identifizierung von indirekten igf- 1-agonisten - Google Patents

Verfahren zur identifizierung von indirekten igf- 1-agonisten

Info

Publication number
ATE439378T1
ATE439378T1 AT06026832T AT06026832T ATE439378T1 AT E439378 T1 ATE439378 T1 AT E439378T1 AT 06026832 T AT06026832 T AT 06026832T AT 06026832 T AT06026832 T AT 06026832T AT E439378 T1 ATE439378 T1 AT E439378T1
Authority
AT
Austria
Prior art keywords
igf
agonists
identifying
identifying indirect
relates
Prior art date
Application number
AT06026832T
Other languages
English (en)
Inventor
Michelle Schaffer
Mark Ultsch
Felix Vajdos
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE439378T1 publication Critical patent/ATE439378T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
AT06026832T 2001-02-09 2002-02-01 Verfahren zur identifizierung von indirekten igf- 1-agonisten ATE439378T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26797701P 2001-02-09 2001-02-09
US28707201P 2001-04-27 2001-04-27

Publications (1)

Publication Number Publication Date
ATE439378T1 true ATE439378T1 (de) 2009-08-15

Family

ID=26952796

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06026832T ATE439378T1 (de) 2001-02-09 2002-02-01 Verfahren zur identifizierung von indirekten igf- 1-agonisten
AT02724908T ATE349469T1 (de) 2001-02-09 2002-02-01 Kristallisierung von igf-1

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02724908T ATE349469T1 (de) 2001-02-09 2002-02-01 Kristallisierung von igf-1

Country Status (19)

Country Link
US (8) US7084240B2 (de)
EP (3) EP1358209B1 (de)
JP (2) JP4489352B2 (de)
KR (1) KR100872613B1 (de)
CN (1) CN100439397C (de)
AT (2) ATE439378T1 (de)
AU (1) AU2002255508B2 (de)
BR (1) BR0207422A (de)
CA (1) CA2431033A1 (de)
DE (3) DE60217066D1 (de)
DK (2) DK1358209T3 (de)
ES (2) ES2331150T3 (de)
HU (1) HUP0500733A3 (de)
IL (2) IL156435A0 (de)
MX (1) MXPA03007042A (de)
NZ (3) NZ548358A (de)
PL (1) PL374181A1 (de)
WO (1) WO2002064627A2 (de)
ZA (1) ZA200304900B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1401476A4 (de) * 2001-03-14 2006-03-08 Genentech Inc Igf-antagonistenpeptide
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
ATE382364T1 (de) * 2001-09-18 2008-01-15 Bioexpertise Llc Von igf-bindungsprotein stammendes peptid
US6914049B2 (en) 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
WO2004102151A2 (en) * 2003-05-06 2004-11-25 New Century Pharmaceuticals Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on therir albumin binding properties
CA2585115A1 (en) * 2003-11-03 2005-05-12 New Century Pharmaceuticals, Inc. Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties
CN101829319A (zh) 2003-12-08 2010-09-15 Cpex药品公司 用于胰岛素治疗的药用组合物及方法
US20060003931A1 (en) * 2004-05-06 2006-01-05 Genentech, Inc. Crystal structure of the hepatocyte growth factor and methods of use
US20060069019A1 (en) * 2004-05-06 2006-03-30 Genentech, Inc. Crystal structure of the complex of hepatocyte growth factor beta chain with Met receptor and methods of use
PT1773878E (pt) 2004-07-19 2015-06-05 Biocon Ltd Conjugados de insulina-oligómero, formulaçôes e usos dos mesmos
JP2008514240A (ja) * 2004-10-01 2008-05-08 インヴィトロジェン コーポレーション 生体分子のインビトロ合成用の供給バッファー、系、及び方法
US7556776B2 (en) * 2005-09-08 2009-07-07 President And Fellows Of Harvard College Microfluidic manipulation of fluids and reactions
BRPI0812768A2 (pt) * 2007-06-08 2014-12-02 Massachusetts Inst Technology Igf para o tratamento de síndrome de rett e transtornos sinápticos.
US8350007B2 (en) 2007-08-17 2013-01-08 The Regents Of The University Of California Crystal structure of human mitoNEET protein
CN101139391B (zh) * 2007-08-21 2012-07-25 陈志南 Cd147胞外区晶体结构及应用
WO2009134395A2 (en) 2008-04-28 2009-11-05 President And Fellows Of Harvard College Microfluidic device for storage and well-defined arrangement of droplets
JP5571186B2 (ja) * 2009-07-22 2014-08-13 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ ５９位にアミノ酸置換を有するインスリン様増殖因子−１（ｉｇｆ−１）の類似体
WO2011011071A2 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1)
WO2011047204A1 (en) * 2009-10-14 2011-04-21 Mount Sinai School Of Medicine Method of treating memory disorders and enhancing memory using igf-ii compounds
EP2830625A1 (de) * 2012-03-28 2015-02-04 Merck Sharp & Dohme Corporation Hemmer des insulinähnlichen wachstumsfaktor-1-rezeptors
KR101711584B1 (ko) * 2012-12-18 2017-03-02 재단법인 의약바이오컨버젼스연구단 변형된 eprs 단백질의 결정 구조 및 이의 결정화 방법
KR102313381B1 (ko) 2013-12-19 2021-10-14 퓨어테인 바이오사이언스, 엘엘씨. 동물을 치료하기 위한 방법
JP2022547948A (ja) 2019-09-09 2022-11-16 ザ・ユニバーシティ・オブ・シカゴ 片頭痛の処置のための併用療法
WO2021248160A1 (en) * 2020-06-01 2021-12-09 Loma Linda University Health Methods of treatment of a cytokine storm

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US589867A (en) * 1897-09-14 Clothes-line hanger
US577276A (en) * 1897-02-16 Quarter-saver iv
US4672108A (en) * 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
ATE81779T1 (de) * 1985-08-22 1992-11-15 Gropep Pty Ltd Peptidanalogedes insulinaehnlichen wachstumsfaktors-1 bei saeugetieren.
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
ATE116335T1 (de) * 1987-12-24 1995-01-15 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).
US5470828A (en) * 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
ATE86496T1 (de) * 1988-02-05 1993-03-15 Ciba Geigy Ag Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten.
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
GB8920381D0 (en) 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5028224A (en) * 1990-01-09 1991-07-02 Kimberly-Clark Corporation Apparatus for intermittently depositing particulate material in a substrate
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
SE9100099D0 (sv) 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
DK0597033T3 (da) * 1991-08-01 1997-06-02 Genentech Inc IGF-1 til forbedring af den neurale tilstand
US5126314A (en) * 1991-09-06 1992-06-30 Eastman Kodak Company Mixture of dyes for black dye donor for thermal color proofing
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
CA2135306A1 (en) 1992-05-08 1993-11-25 Bradford A. Jameson Igf-1 analogs
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
US5866114A (en) 1992-06-09 1999-02-02 Chiron Corporation Crystallization of M-CSFα
DE69327402T2 (de) * 1992-06-12 2000-05-04 Albert Einstein College Of Medicine Of Yeshiva University, Bronx Vorbeugung und behandlung der peripheren neuropathie
NZ255461A (en) 1992-08-20 1996-12-20 Biotechnology & Biolog Science Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
AU683043B2 (en) 1993-01-25 1997-10-30 Beth Israel Hospital Association, The Method for modifying, diagnosing, and screening for IGF-I sensitive cell barrier properties
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
US5407810A (en) 1993-08-20 1995-04-18 Genentech, Inc. Aqueous multiple-phase isolation of polypeptide
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
SE9402370D0 (sv) 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
SE9501472D0 (sv) 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
EP0833847B1 (de) 1995-06-22 2003-09-24 Biogen, Inc. Kristalle von fragmenten von cd40-liganden und deren verwendung
US5948751A (en) * 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
JP3417230B2 (ja) * 1996-09-25 2003-06-16 信越化学工業株式会社 型取り母型用光硬化性液状シリコーンゴム組成物
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
US5898028A (en) * 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
JP2002510321A (ja) 1997-07-03 2002-04-02 スミスクライン・ビーチャム・コーポレイション 抗−第ＩＸ因子 Ｆａｂフラグメントの結晶構造およびペプチド模倣物デザインのための使用方法
US5876242A (en) * 1997-07-21 1999-03-02 Williams; Hugh D. Remote battery extension apparatus
CA2319252C (en) 1998-01-21 2004-11-30 Brigham And Women's Hospital, Inc. Circulating insulin-like growth factor-i and prostate cancer risk
WO2000023469A2 (en) 1998-10-16 2000-04-27 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
JP2004512010A (ja) 2000-03-29 2004-04-22 ディージーアイ・バイオテクノロジーズ・エル・エル・シー インスリン及びｉｇｆ−１受容体のアゴニスト及びアンタゴニスト
JP2005508295A (ja) 2001-06-07 2005-03-31 エフ．ホフマン−ラ　ロシュ　アーゲー Ｉｇｆ結合タンパク質の変異体、およびそれらのアゴニストの作製法
US20040137518A1 (en) * 2002-01-31 2004-07-15 Lambert Millard Hurst CRYSTALLIZED PPARa LIGAND BINDING DOMAIN POLYPEPTIDE AND SCREENING METHODS EMPLOYING SAME
JP3680801B2 (ja) * 2002-02-27 2005-08-10 株式会社デンソー 回転電機の巻線接合方法

Also Published As

Publication number Publication date
EP1358209B1 (de) 2006-12-27
US7354769B2 (en) 2008-04-08
JP4489352B2 (ja) 2010-06-23
NZ526672A (en) 2006-10-27
US7297763B2 (en) 2007-11-20
DE60217066D1 (de) 2007-02-08
EP1358209A2 (de) 2003-11-05
PL374181A1 (en) 2005-10-03
JP2009215299A (ja) 2009-09-24
DK1358209T3 (da) 2007-05-07
ES2278020T3 (es) 2007-08-01
DK1772464T3 (da) 2009-12-14
US20060270839A1 (en) 2006-11-30
ATE349469T1 (de) 2007-01-15
NZ548358A (en) 2008-04-30
BR0207422A (pt) 2005-04-19
US7433788B2 (en) 2008-10-07
US20060281905A1 (en) 2006-12-14
WO2002064627A3 (en) 2003-07-31
US20060287235A1 (en) 2006-12-21
ZA200304900B (en) 2005-07-27
IL156435A0 (en) 2004-01-04
WO2002064627A2 (en) 2002-08-22
US20060287510A1 (en) 2006-12-21
DE60233359D1 (de) 2009-09-24
US7238658B2 (en) 2007-07-03
US7596455B2 (en) 2009-09-29
AU2002255508B2 (en) 2008-04-03
EP1772464A3 (de) 2007-10-03
US20020165155A1 (en) 2002-11-07
JP2005503329A (ja) 2005-02-03
KR100872613B1 (ko) 2008-12-09
CN100439397C (zh) 2008-12-03
US20060276397A1 (en) 2006-12-07
DE60217066T4 (de) 2010-07-01
HK1060138A1 (en) 2004-07-30
HUP0500733A2 (hu) 2005-10-28
CN1703425A (zh) 2005-11-30
EP1772464B1 (de) 2009-08-12
US20060293507A1 (en) 2006-12-28
US7084240B2 (en) 2006-08-01
DE60217066T2 (de) 2007-07-12
KR20040064610A (ko) 2004-07-19
NZ548359A (en) 2007-11-30
MXPA03007042A (es) 2004-05-24
EP1801120A1 (de) 2007-06-27
CA2431033A1 (en) 2002-08-22
US20050215477A1 (en) 2005-09-29
EP1772464A2 (de) 2007-04-11
IL156435A (en) 2009-09-22
ES2331150T3 (es) 2009-12-22
HUP0500733A3 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
ATE439378T1 (de) Verfahren zur identifizierung von indirekten igf- 1-agonisten
ATE310955T1 (de) Zusammensetzungen und verfahren zum nachweis und zur behandlung von mit chemokinrezeptoren verbundenen krankheiten
ATE343591T1 (de) Antagonist für die multimerisierung von hiv-1 vif-protein
WO2008041953A3 (en) Dengue diagnosis and treatment
DE60216245D1 (de) Funktionelles oberflächendisplay von polypeptiden
ATE250143T1 (de) Verfahren und vorrichtung zum nachweis und zur quantifizierung von biomolekülen
DE602004019812D1 (de) Marker für neuromyelitis optica
EP1589106A4 (de) Adiponektin-rezeptor und dafür kodierendes gen
ATE382148T1 (de) Antikörper für apoptosemarker und anwendungsverfahren
ATE479175T1 (de) Bereitstellung von verkehrsinformationen mit unterverknüpfungen von verknüpfungen
ATE333522T1 (de) Verfahren zur bestimmung von mehrere analyten
WO2002086081A3 (en) Methods and systems for identifying proteins
BR0208479B1 (pt) composiÇço e mÉtodo para inibir oxidaÇço em estoques bÁsicos de grupo i de api com teor elevado de enxofre.
ATE389881T1 (de) Detektion von kleinen molekülen mit piezo- elektrischem sensor
NO20052553D0 (no) Cobalaminanalyse.
DE60325640D1 (de) Verfahren zur identifizierung von transmembranrezeptoragonisten mit reduzierter internalisierung
NO20053990L (no) Assay for proteinisoformer
EP1079230A4 (de) Verfahren zum screenen einer die oligomerisierung von rezeptorproteinmolekülen fördernden substanz
WO2004094468A3 (en) Method for identifying an anti-streptococcal agent and its use for treating streptococcal infections
ATE405646T1 (de) Ein verfahren zum auffinden vom prostatakrebs
ATE368126T1 (de) Verfahren zur identifizierung von protein sic inhibitoren
WO2004010108A3 (en) Method for the identification of ligands
DE10293635D2 (de) Träger für immobilisierte Biomoleküle und Verfahren zur Immobilisierung von Biomolekülen
PE20050127A1 (es) Metodos para identificar compuestos para regular la masa o funcion muscular utilizando receptores de dopamina

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1772464

Country of ref document: EP